Manhattan Scientifics Announces Early Results from Cancer Company

Rhea-AI Summary

Manhattan Scientifics Inc. (OTCQB: MHTX) announced positive early results from the human study of Imagion Biosystems' cancer diagnostic technology. Following the announcement, shares of Imagion Biosystems (IBX.AX) surged by 46%, reaching 71 million in trading volume. Manhattan Scientifics owns over 50 million shares of Imagion, indicating a significant investment in the company’s future. The press release highlights the innovative diagnostic technology aimed at early cancer detection, emphasizing its non-radioactive and super-sensitive nature.

Positive

• Manhattan Scientifics reports positive early results from Imagion Biosystems' cancer diagnostic study.
• Imagion Biosystems' shares rose 46% following the announcement.
• Manhattan Scientifics holds over 50 million shares of Imagion, signaling strong investment.

Negative

• None.

NEW YORK--(BUSINESS WIRE)-- Manhattan Scientifics Inc. (OTCQB: MHTX ), announces positive early results from Imagion Biosystems Cancer Diagnostic human study.

Imagion Biosystems Ltd. (IBX.AX) shares were up 46% trading 71 million shares.

Manhattan Scientifics Inc., initially funded and is the current owner of more that 50 million shares of Imagion Biosystems Ltd.

About Manhattan Scientifics, Inc.

Manhattan Scientifics Inc. (www.mhtx.com) is focused on technology transfer and commercialization of transformative technologies. It has assisted incubating and financing four IPO’s working closely with Science Teams at the Los Alamos National Laboratory and the Sandia National Laboratory in New Mexico

About Imagion Biosystems

Imagion Biosystems (www.imagionbiosystems.com)is developing a new non-radioactive and super-sensitive diagnostic imaging technology for very early detection of cancers. Imagion is listed on the Australian Stock Exchange (ASX).

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005587/en/

Manhattan Scientifics, Inc.

Manny Tsoupanarias, 917-688-4158

Manny@mhtx.com

Or

Marvin Maslow, 917-923-3300

Marvin@mhtx.com

Source: Manhattan Scientifics Inc.

FAQ

What are the early results reported by Manhattan Scientifics regarding Imagion Biosystems?

Manhattan Scientifics announced positive early results from the human study of Imagion Biosystems' cancer diagnostic technology.

How much did Imagion Biosystems' shares increase after the news?

Imagion Biosystems' shares increased by 46% after the announcement.

What is the stock symbol for Manhattan Scientifics?

The stock symbol for Manhattan Scientifics is OTCQB: MHTX.

How many shares does Manhattan Scientifics own in Imagion Biosystems?

Manhattan Scientifics owns over 50 million shares of Imagion Biosystems.